Barclays (LON:BARC) analyst Gena Wang maintained a Hold rating on Editas Medicine (NASDAQ:EDIT) Inc on Monday, setting a price target of $39, which is approximately 3.87% below the present share price of $40.57.
Wang expects Editas Medicine Inc to post earnings per share (EPS) of -$0.81 for the fourth quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in Editas Medicine, with an average price target of $60.86.
The analysts price targets range from a high of $80 to a low of $41.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $379 thousand and a net profit of -$55.4 million. The company's market cap is $2.77 billion.
According to TipRanks.com, Barclays analyst Gena Wang is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 18.5% and a 49.43% success rate.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.